ALSO NOTED: Paion inks $102M deal; Sepracor chairman plans retirement years;and much more...

> Sepracor Chairman Timothy Barberich is planning to retire. He will receive $1.65 million a year under a retirement pact. Report

> After being abandoned by Forest Laboratories, Germany's Paion has inked a $102 million development deal for the stroke drug desmoteplase. Release

> Forest Labs and Cypress Biosciences have submitted an NDA for milnacipran for fibromyalgia syndrome. Release

> The UK's Axa Framlington Health says the threat of an economic slowdown has not hampered its investment strategy in biotech. Report

> The CEO of Charles River Laboratories has exercised his options for 30,000 shares of common stock. Report

And Finally… We weren't the only ones to take a look back at 2007. Here's the Guardian's take on the year past. Article 

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.